Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NNNN | 6-K | neutral | 4/10 | Anbio Biotechnology held an EGM on May 15, 2026, approving a share capital reduction, a massive increase in authorized s | May 19, 2026 |
| IPHYF | 6-K | neutral | 2/10 | Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global Heal | May 19, 2026 |
| CMND | PRESS-RELEASE | bearish | 5/10 | Clearmind Medicine announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compliance with Nasdaq's m | May 19, 2026 |
| RLAY | PRESS-RELEASE | bullish | 7/10 | Relay Therapeutics reported promising initial Phase 2 data for zovegalisib in PIK3CA-driven vascular anomalies, showing | May 19, 2026 |
| HRMY | 3 | neutral | 5/10 | Geno Germano filed an initial Form 3 statement of beneficial ownership with the SEC, listing himself as a reporting insi | May 18, 2026 |
| MPLT | CLUSTER | bearish | 5/10 | CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1 2026 results (net l | May 18, 2026 |
| ARTV | 144 | neutral | 2/10 | Artiva Biotherapeutics (ARTV) director Christopher Horan filed a Form 144 to sell 7,500 shares (~$69K estimated value) a | May 18, 2026 |
| ARTV | 144 | neutral | 2/10 | Jennifer Bush, an officer and director of Artiva Biotherapeutics, filed a Form 144 to sell 9,000 shares of common stock | May 18, 2026 |
| TLPPF | 3 | neutral | 2/10 | David N. Gill filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities beneficiall | May 18, 2026 |
| TLPPF | 3 | neutral | 2/10 | William Jellison filed a Form 3 initial statement of beneficial ownership with Telix Pharmaceuticals Ltd, reporting no s | May 18, 2026 |
| TLPPF | 3 | neutral | 2/10 | Maria Rivas filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities owned in Teli | May 18, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt, CFO James Edgemond, and Director Nilda Mesa sold a total of ~$1.03M in UTHR shares over the past | May 18, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two senior insiders at Oruka Therapeutics (CMO & SVP Finance) collectively sold ~$540K of stock on May 15-18, 2026, foll | May 18, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Two NBIX directors sold $2.96M in shares over a 4-day window, representing a trivial 0.019% of market cap. Sales occurre | May 18, 2026 |
| CGEM | 8-K | bullish | 5/10 | Cullinan Therapeutics announced initial Phase 1 clinical data for CLN-978 in RA and SLE, showing robust B cell depletion | May 18, 2026 |
| IBRX | 8-K | bullish | 5/10 | ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strai | May 18, 2026 |
| INAB | S-3/A | bearish | 7/10 | IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity f | May 18, 2026 |
| FENC | 8-K | neutral | 2/10 | Fennec Pharmaceuticals filed an 8-K reporting the grant of stock options to purchase 50,000 common shares to three new n | May 18, 2026 |
| PTN | 8-K | neutral | 4/10 | Palatin Technologies voluntarily transfers its common stock listing from NYSE American to Nasdaq Capital Market, with tr | May 18, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | CEO Jason Coloma and President/CMO Harold Bernstein sold a combined $441K in open-market shares within days of Maze Ther | May 18, 2026 |
| HOWL | 144 | bearish | 6/10 | Three MPM-affiliated funds (MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., and MPM Oncology Innovations Fun | May 18, 2026 |
| NTHI | 8-K | mixed | 5/10 | NeOnc reported Q1 2026 net loss of $8.8M (-$0.38/sh) vs consensus -$0.30, a 26.7% miss, but this is typical for pre-reve | May 18, 2026 |
| CGEM | PRESS-RELEASE | neutral | 5/10 | Cullinan Therapeutics announced that interim Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in RA and SLE will be pr | May 18, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblasto | May 18, 2026 |
| CRVO | 8-K | bearish | 6/10 | CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9M, providing runway | May 18, 2026 |
| ARTL | 424B5 | neutral | 4/10 | Artelo Biosciences terminated its At-The-Market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 20 | May 18, 2026 |
| WVE | PRESS-RELEASE | bullish | 7/10 | Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT | May 18, 2026 |
| QUCY | 144 | bearish | 5/10 | Guido Baechler, a policy-making officer, filed a Form 144 indicating intent to sell 200,000 common shares (estimated val | May 18, 2026 |
| ALMS | DEFA14A | neutral | 3/10 | Alumis Inc. filed a DEFA14A soliciting material for its 2026 Annual Meeting, proposing the election of three Class II di | May 18, 2026 |
| INVA | 8-K | neutral | 3/10 | Innoviva reported the resignations of board members Derek Small and Mark DiPaolo to focus on their roles at Syndeio BioS | May 18, 2026 |